FEIBA

Also found in: Acronyms.

FEIBA

Factor VIII inhibitor–see there, or factor VIII bypassing activity. See Prothrombin complex concentrate.

Mentioned in ?

prothrombin complex concentrate

References in periodicals archive ?

Aherens et al., "The role of FEIBA in reversing novel oral anticoagulants in intracerebral hemorrhage," Neurocritical Care, vol.

Reversal Strategies for Intracranial Hemorrhage Related to Direct Oral Anticoagulant Medications

In rats receiving rivaroxaban, high-dose 4F-PCC was shown to produce the most profound decrease in mesenteric bleeding time (versus FEIBA and activated factor VII).

Clinical Applications of 4-Factor Prothrombin Complex Concentrate: A Practical Pathologist's Perspective

The approval is based on data from a Phase III trial known as FEIBA PROOF, under which treatment with a FEIBA prophylactic regimen indicated a 72% reduction in median annual bleed rate against treatment with an on-demand regimen.

Baxter International receives approval for FEIBA

(11,12) Treatment strategies to control active bleeding include the use of desmopressin (DDAVP), Factor VIII concentrate, activated prothrombin complex or APC (FEIBA - Anti-inhibitor coagulant factor), and Recombinant VIIa (NovoSeven).

Acquired hemophilia: a clinical experience

Specialised 'bypass' therapies such as FEIBA or Novoseven have been developed, and require highly specialised input as they are extremely expensive, and may not be effective if given incorrectly.

Haemophilia emergencies

Porcine factor VIII and activated factor VII are new products for this type of patient, and prothrombin complex concentrates (Autoplex[R] and Feiba) are used (79).

Coagulation and bleeding disorders: review and update

No se debe usar con FEIBA u otro concentrado de complejo protrombinico, porque potencian los efectos trombogenicos (8).

Hemofilia: terapeutica en las alteraciones hemostaticas. Parte I

have reviewed all reported patients with hemophilia A and hemophilia B in the literature and found that the administration of factor VIII inhibitor bypassing activity (FEIBA) or recombinant activated FVII (rFVIIa) in patients with inhibitors and surgery was the most frequent risk factor for thromboembolism development in hemophilia A and B patients, respectively, in addition to variable prothrombotic conditions and administration of prothrombin complex concentrate (PCC) [9].

Upper Limb Deep Vein Thrombosis in Patient with Hemophilia A and Heterozygosity for Prothrombin G20210A: A Case Report and Review of the Literature

Comments: Hematology revenues were $855 million, excluding the impact of foreign exchange, grew 6% in the quarter driven by ADVATE, a treatment for hemophilia A, and double-digit growth of FEIBA, an inhibitor treatment.